Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evolution of echocardiography in subclinical detection of cancer therapy–related cardiac dysfunction

Evolution of echocardiography in subclinical detection of cancer therapy–related cardiac dysfunction Cancer therapies have resulted in increased survivorship in oncological patients. However, the benefits have been marred by the development of premature cardiovascular disease. The current definition outlines measurement of ejection fraction as a mean to diagnose cancer therapeutic–related cardiac dysfunction (CTRCD); however, up to 58% of the patients do not regain their cardiac function after the CTRCD diagnosis, despite therapeutic interventions. Therefore, there has been a growing interest in the markers for early myocardial changes (ie, changes with normal left ventricular ejection fraction [LVEF]) that may predict the development of subsequent left ventricular ejection fraction reduction or progression to heart failure. This review will highlight the use of diastolic parameters, tissue Doppler imaging (TDI), and speckle tracking echocardiogram (STE) as emerging technologies which can potentially detect cardiac dysfunction thereby stratifying patients for cardioprotective therapies. The goal of this manuscript was to highlight the concepts and discuss the current controversies surrounding these echocardiographic imaging modalities. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Echocardiography Wiley

Evolution of echocardiography in subclinical detection of cancer therapy–related cardiac dysfunction

Download PDF
9 pages

Loading next page...
 
/lp/wiley/evolution-of-echocardiography-in-subclinical-detection-of-cancer-b7uVpj2TYq
Publisher
Wiley
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0742-2822
eISSN
1540-8175
DOI
10.1111/echo.14012
pmid
29749652
Publisher site
See Article on Publisher Site

Abstract

Cancer therapies have resulted in increased survivorship in oncological patients. However, the benefits have been marred by the development of premature cardiovascular disease. The current definition outlines measurement of ejection fraction as a mean to diagnose cancer therapeutic–related cardiac dysfunction (CTRCD); however, up to 58% of the patients do not regain their cardiac function after the CTRCD diagnosis, despite therapeutic interventions. Therefore, there has been a growing interest in the markers for early myocardial changes (ie, changes with normal left ventricular ejection fraction [LVEF]) that may predict the development of subsequent left ventricular ejection fraction reduction or progression to heart failure. This review will highlight the use of diastolic parameters, tissue Doppler imaging (TDI), and speckle tracking echocardiogram (STE) as emerging technologies which can potentially detect cardiac dysfunction thereby stratifying patients for cardioprotective therapies. The goal of this manuscript was to highlight the concepts and discuss the current controversies surrounding these echocardiographic imaging modalities.

Journal

Echocardiography – Wiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

  • Cancer statistics, 2018
    Siegel, RL; Miller, KD; Jemal, A
  • Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond
    Moudgil, R; Yeh, ET
  • Cardiac dysfunction in the trastuzumab clinical trials experience
    Seidman, A; Hudis, C; Pierri, MK
  • 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    Yancy, CW; Jessup, M; Bozkurt, B
  • Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy
    Thavendiranathan, P; Grant, AD; Negishi, T
  • Anthracycline‐induced cardiomyopathy: clinical relevance and response to pharmacologic therapy
    Cardinale, D; Colombo, A; Lamantia, G
  • Trastuzumab‐induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation
    Cardinale, D; Colombo, A; Torrisi, R
  • The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II‐positive breast cancer treated with adjuvant trastuzumab therapy
    Fallah‐Rad, N; Walker, JR; Wassef, A
  • Trastuzumab‐related cardiotoxicity: calling into question the concept of reversibility
    Telli, ML; Hunt, SA; Carlson, RW; Guardino, AE
  • Protective effects of carvedilol against anthracycline‐induced cardiomyopathy
    Kalay, N; Basar, E; Ozdogru, I
  • Protective effects of nebivolol against anthracycline‐induced cardiomyopathy: a randomized control study
    Kaya, MG; Ozkan, M; Gunebakmaz, O
  • Cardioprotective effect of beta‐adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow‐up study of heart failure
    Seicean, S; Seicean, A; Alan, N; Plana, JC; Budd, GT; Marwick, TH
  • Prevention of high‐dose chemotherapy‐induced cardiotoxicity in high‐risk patients by angiotensin‐converting enzyme inhibition
    Cardinale, D; Colombo, A; Sandri, MT
  • Long‐term enalapril therapy for left ventricular dysfunction in doxorubicin‐treated survivors of childhood cancer
    Lipshultz, SE; Lipsitz, SR; Sallan, SE
  • The effect of dexrazoxane on myocardial injury in doxorubicin‐treated children with acute lymphoblastic leukemia
    Lipshultz, SE; Rifai, N; Dalton, VM
  • Assessment of dexrazoxane as a cardioprotectant in doxorubicin‐treated children with high‐risk acute lymphoblastic leukaemia: long‐term follow‐up of a prospective, randomised, multicentre trial
    Lipshultz, SE; Scully, RE; Lipsitz, SR
  • Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group
    Seymour, L; Bramwell, V; Moran, LA
  • ICRF‐187 permits longer treatment with doxorubicin in women with breast cancer
    Speyer, JL; Green, MD; Zeleniuch‐Jacquotte, A
  • The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review
    Swain, SM; Vici, P
  • Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin‐induced systolic dysfunction in humans
    Stoddard, MF; Seeger, J; Liddell, NE; Hadley, TJ; Sullivan, DM; Kupersmith, J
  • Myocardial dysfunction late after low‐dose anthracycline treatment in asymptomatic pediatric patients
    Ganame, J; Claus, P; Uyttebroeck, A
  • Subclinical anthracycline‐ and trastuzumab‐induced cardiotoxicity in the long‐term follow‐up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study
    Ho, E; Brown, A; Barrett, P
  • Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study
    Tassan‐Mangina, S; Codorean, D; Metivier, M
  • Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics
    Marchandise, B; Schroeder, E; Bosly, A
  • Ability of nonstrain diastolic parameters to predict doxorubicin‐induced cardiomyopathy: a systematic review with meta‐analysis
    Nagiub, M; Nixon, JV; Kontos, MC
  • Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function
    Dorup, I; Levitt, G; Sullivan, I; Sorensen, K
  • Cardiac diastolic function in pediatric patients receiving doxorubicin
    Ewer, MS; Ali, MK; Gibbs, HR
  • Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood
    Iarussi, D; Galderisi, M; Ratti, G
  • Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin‐treated patients and its correlation to conventional echo/Doppler indices
    Ocal, B; Oguz, D; Karademir, S
  • Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study
    Sorensen, K; Levitt, GA; Bull, C; Dorup, I; Sullivan, ID
  • Pulsed tissue Doppler illustrated to a resident in cardiology
    Galderisi, M; Nistri, S; Ansalone, G
  • Differentiation of constrictive pericarditis from restrictive cardiomyopathy: assessment of left ventricular diastolic velocities in longitudinal axis by Doppler tissue imaging
    Garcia, MJ; Rodriguez, L; Ares, M; Griffin, BP; Thomas, JD; Klein, AL
  • Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures
    Nagueh, SF; Middleton, KJ; Kopelen, HA; Zoghbi, WA; Quiñones, MA
  • Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function
    Sohn, DW; Chai, IH; Lee, DJ
  • Tissue Doppler and myocardial deformation imaging to detect myocardial dysfunction in pediatric cancer patients treated with high doses of anthracyclines
    Yagci‐Kupeli, B; Varan, A; Yorgun, H; Kaya, B; Büyükpamukçu, M
  • Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography
    Mor‐Avi, V; Lang, RM; Badano, LP
  • Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long‐term observational study of outcome in 120 patients
    Jensen, BV; Skovsgaard, T; Nielsen, SL
  • Two‐dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy
    Stoodley, PW; Richards, DA; Hui, R
  • Echocardiographic assessment of myocardial strain
    Gorcsan, J; Tanaka, H
  • Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer
    Jurcut, R; Wildiers, H; Ganame, J
  • Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab
    Hare, JL; Brown, JK; Leano, R; Jenkins, C; Woodward, N; Marwick, TH
  • Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy
    Cheung, YF; Hong, WJ; Chan, GC; Wong, SJ; Ha, SY
  • Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
    Plana, JC; Galderisi, M; Barac, A
  • Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1
    Chang, HM; Moudgil, R; Scarabelli, T; Okwuosa, TM; Yeh, ETH
  • Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
    Curigliano, G; Cardinale, D; Suter, T
  • A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology
    Maurea, N; Spallarossa, P; Cadeddu, C
  • 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
    Zamorano, JL; Lancellotti, P; Rodriguez Muñoz, D
  • Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy
    Virani, SA; Dent, S; Brezden‐Masley, C
  • Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study
    Mavinkurve‐Groothuis, AM; Marcus, KA; Pourier, M
  • Torsion analysis in the early detection of anthracycline‐mediated cardiomyopathy
    Motoki, H; Koyama, J; Nakazawa, H
  • Capecitabine‐related cardiotoxicity: recognition and management
    Saif, MW; Tomita, M; Ledbetter, L; Diasio, RB
  • Early detection of anthracycline‐mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist
    Mornos, C; Petrescu, L
  • Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
    Plana, JC; Galderisi, M; Barac, A
  • A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology
    Maurea, N; Spallarossa, P; Cadeddu, C
  • 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
    Zamorano, JL; Lancellotti, P; Rodriguez Munoz, D
  • American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
    Runowicz, CD; Leach, CR; Henry, NL
  • Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology
    Gradishar, WJ; Anderson, BO; Balassanian, R
  • Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines
    Curigliano, G; Cardinale, D; Suter, T
  • Canadian cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy
    Virani, SA; Dent, S; Brezden‐Masley, C
  • Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1
    Chang, HM; Moudgil, R; Scarabelli, T; Okwuosa, TM; Yeh, ETH
  • Left ventricular twisting and untwisting motion in childhood cancer survivors
    Cheung, YF; Li, SN; Chan, GC; Wong, SJ; Ha, SY
  • Persistence, up to 18 months of follow‐up, of epirubicin‐induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers
    Mantovani, G; Madeddu, C; Cadeddu, C
  • Left ventricular function assessed by two‐dimensional speckle tracking echocardiography in long‐term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy
    Tsai, HR; Gjesdal, O; Wethal, T
  • Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction
    Aljaroudi, W; Alraies, MC; Halley, C
  • Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle‐aged and elderly adults: the Strong Heart Study
    Bella, JN; Palmieri, V; Roman, MJ
  • Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction
    Daugaard, G; Lassen, U; Bie, P
  • Mortality rate in patients with diastolic dysfunction and normal systolic function
    Halley, CM; Houghtaling, PL; Khalil, MK; Thomas, JD; Jaber, WA
  • Cardiomyopathy with restrictive physiology in sickle cell disease
    Niss, O; Quinn, CT; Lane, A